Cleared Traditional

K890189 - AGEN DIMERTEST EIA

K890189 is the FDA 510(k) clearance for AGEN DIMERTEST EIA by Agen Biomedical , Ltd.. It is a Class 2 Hematology device (product code DAP) cleared through the Traditional 510(k) pathway after a 45-day FDA review.

K890189 · Agen Biomedical , Ltd. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1989
Decision
45d
Days
Class 2
Risk

K890189 is an FDA 510(k) clearance for the AGEN DIMERTEST EIA. Classified as Fibrinogen And Fibrin Split Products, Antigen, Antiserum, Control (product code DAP), Class II - Special Controls.

Submitted by Agen Biomedical , Ltd. (Parsippany, US). The FDA issued a Cleared decision on March 3, 1989 after a review of 45 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7320 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Agen Biomedical , Ltd. devices

Submission Details

510(k) Number K890189 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 17, 1989
Decision Date March 03, 1989
Days to Decision 45 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
68d faster than avg
Panel avg: 113d · This submission: 45d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DAP Fibrinogen And Fibrin Split Products, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7320
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - DAP Fibrinogen And Fibrin Split Products, Antigen, Antiserum, Control

All 44
Devices cleared under the same product code (DAP) and FDA review panel - the closest regulatory comparables to K890189.
FIBRINOSTIKA TDP MICROELISA SYSTEM
K915698 · Organon Teknika Corp. · Aug 1992
FDP PLASMA TEST KIT
K920943 · American Bioproducts Co. · Jul 1992
FIBRINOSTIKA FBDP MICROELISA SYSTEM
K912876 · Organon Teknika Corp. · Oct 1991
DATA-FI DIMERTEST LATEX ASSAY
K872195 · American Dade · Aug 1987
ASSERACHROM D-DI KIT
K862156 · American Bioproducts Co. · Sep 1986